🔎 Trials Near Me

Hjem › Akut myelogen leukemi › Rhode Island › Providence

Kliniske studier for Akut myelogen leukemi i Providence, RI

10 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Providence (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • Rhode Island Hospital, Providence
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05564390

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

RekruttererFase 3
  • Clinical Trial Site, Providence
Alder 12 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07211958

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Rhode Island Hospital, Providence
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Rhode Island Hospital, Providence
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Rhode Island Hospital, Providence
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • Rhode Island Hospital, Providence
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

RekruttererFase 2/3
  • University of Rhode Island, Providence
Alder 18 til 80 · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06788756

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

RekruttererFase 2
  • Lifespan Health System Rhode Island Hospital, Providence
Alder 18 og eldre · Alle kjønn · Oppdatert 10. jul. 2026 · NCT05442216

Akut myelogen leukemi-studier i andre byer

Andre studier i Providence

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.